These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 32607825)

  • 1. Cardiovascular Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    Pineda-Gayoso R; Alomar M; Lee DH; Fradley MG
    Curr Treat Options Oncol; 2020 Jun; 21(8):67. PubMed ID: 32607825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical.
    Dong R; Yan Y; Zeng X; Lin N; Tan B
    Drug Des Devel Ther; 2022; 16():3225-3239. PubMed ID: 36164415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.
    Sestier M; Hillis C; Fraser G; Leong D
    Curr Oncol Rep; 2021 Aug; 23(10):113. PubMed ID: 34342738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
    Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification.
    Patel JN; Singh J; Ghosh N
    Oncotarget; 2024 Jun; 15():355-359. PubMed ID: 38829647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
    Ran F; Liu Y; Wang C; Xu Z; Zhang Y; Liu Y; Zhao G; Ling Y
    Eur J Med Chem; 2022 Feb; 229():114009. PubMed ID: 34839996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of cardiovascular complications of bruton tyrosine kinase inhibitors.
    Tang CPS; Lip GYH; McCormack T; Lyon AR; Hillmen P; Iyengar S; Martinez-Calle N; Parry-Jones N; Patten PEM; Schuh A; Walewska R;
    Br J Haematol; 2022 Jan; 196(1):70-78. PubMed ID: 34498258
    [No Abstract]   [Full Text] [Related]  

  • 8. Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens.
    Hopkins BT; Bame E; Bell N; Bohnert T; Bowden-Verhoek JK; Bui M; Cancilla MT; Conlon P; Cullen P; Erlanson DA; Fan J; Fuchs-Knotts T; Hansen S; Heumann S; Jenkins TJ; Marcotte D; McDowell B; Mertsching E; Negrou E; Otipoby KL; Poreci U; Romanowski MJ; Scott D; Silvian L; Yang W; Zhong M
    Bioorg Med Chem; 2019 Jul; 27(13):2905-2913. PubMed ID: 31138459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
    da Cunha-Bang C; Niemann CU
    Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
    Bond DA; Alinari L; Maddocks K
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):223-233. PubMed ID: 31188814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.
    Taneja A; Jones J; Pittaluga S; Maric I; Farooqui M; Ahn IE; Wiestner A; Sun C
    Leuk Lymphoma; 2019 Feb; 60(2):519-522. PubMed ID: 29978754
    [No Abstract]   [Full Text] [Related]  

  • 12. Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors.
    Fleming MR; Xiao L; Jackson KD; Beckman JA; Barac A; Moslehi JJ
    Circ Res; 2021 Jun; 128(12):1973-1987. PubMed ID: 34110908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Tran PN; O'Brien S
    Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
    Tang CPS; McMullen J; Tam C
    Leuk Lymphoma; 2018 Jul; 59(7):1554-1564. PubMed ID: 28901789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
    Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
    Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
    Kriegsmann K; Kriegsmann M; Witzens-Harig M
    Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies.
    Gu D; Tang H; Wu J; Li J; Miao Y
    J Hematol Oncol; 2021 Mar; 14(1):40. PubMed ID: 33676527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.
    Lucas F; Woyach JA
    Target Oncol; 2019 Apr; 14(2):125-138. PubMed ID: 30927175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.